These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2696038)

  • 1. Dose response for adjuvant chemotherapy of breast cancer: experimental and clinical considerations.
    Frei E
    Recent Results Cancer Res; 1989; 115():25-7. PubMed ID: 2696038
    [No Abstract]   [Full Text] [Related]  

  • 2. Start tamoxifen after completing chemotherapy, US researchers say.
    McCarthy M
    Lancet; 2002 Jun; 359(9321):1925. PubMed ID: 12057564
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy.
    Hryniuk WM
    Recent Results Cancer Res; 1989; 115():17-24. PubMed ID: 2696029
    [No Abstract]   [Full Text] [Related]  

  • 4. [Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial].
    Amadori D; Fabbri M
    Tumori; 2001; 87(5):A18-9. PubMed ID: 11765729
    [No Abstract]   [Full Text] [Related]  

  • 5. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer.
    Buzdar AU; Smith TL; Marcus CE; Hortobagyi GN; Blumenschein GR
    Recent Results Cancer Res; 1984; 96():141-7. PubMed ID: 6396767
    [No Abstract]   [Full Text] [Related]  

  • 6. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva FJ; Hortobagyi GN
    J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
    [No Abstract]   [Full Text] [Related]  

  • 7. [High-dose chemotherapy rescued with peripheral blood stem cell transplantation for high-risk patients with breast cancer].
    Kim S; Shiba E; Taguchi T; Kimoto Y; Inoue T; Shimazu K; Takamura Y; Tanji Y; Izukura M; Ogawa H; Sugiyama H; Kubota T; Kimura T; Takai S
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):635-8. PubMed ID: 8678525
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant chemotherapy for node-negative breast cancer patients.
    Bonadonna G; Zambetti M; Valagussa P
    Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
    Alagaratnam TT; Wong J
    Aust N Z J Surg; 1986 Jan; 56(1):39-41. PubMed ID: 3090987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.
    Emens LA; Armstrong D; Biedrzycki B; Davidson N; Davis-Sproul J; Fetting J; Jaffee E; Onners B; Piantadosi S; Reilly RT; Stearns V; Tartakovsky I; Visvanathan K; Wolff A
    Hum Gene Ther; 2004 Mar; 15(3):313-37. PubMed ID: 15018740
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant docetaxel for node-positive breast cancer.
    Ahluwalia MS; Daw HA
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16135845
    [No Abstract]   [Full Text] [Related]  

  • 13. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
    Fumoleau P; Bonneterre J; Luporsi E
    J Clin Oncol; 2003 Mar; 21(6):1190-1; author reply 1191-2. PubMed ID: 12637489
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant docetaxel for node-positive breast cancer.
    Noronha V
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
    [No Abstract]   [Full Text] [Related]  

  • 16. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide for metastatic breast cancer.
    Atkins CD
    J Clin Oncol; 2001 Jul; 19(14):3441-2. PubMed ID: 11454896
    [No Abstract]   [Full Text] [Related]  

  • 18. The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.
    Bonadonna G; Valagussa P; Zambetti M; Brambilla C
    Recent Results Cancer Res; 1989; 115():113-7. PubMed ID: 2696023
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
    Ang PT; Buzdar AU; Smith TL; Kau S; Hortobagyi GN
    J Clin Oncol; 1989 Nov; 7(11):1677-84. PubMed ID: 2809682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage treatments in relapsing resectable breast cancer.
    Valagussa P; Brambilla C; Zambetti M; Bonadonna G
    Recent Results Cancer Res; 1989; 115():69-76. PubMed ID: 2696043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.